Vertex, riding high on Trikafta, isn’t just a rare disease company, execs say
Vertex, riding high on Trikafta, isn’t just a rare disease [...]
Vertex, riding high on Trikafta, isn’t just a rare disease [...]
Fierce Pharma Asia—Enhertu’s breast cancer nod; Biogen, Eisai’s next play; [...]
Dupixent retakes TV ad spending crown but overall outlay for [...]
‘Who wants to make money?’ Court documents outline wild fraud [...]
Novartis halts US production of radioligand cancer therapies, citing potential [...]
Intercept sells Ocaliva rights outside the US after NASH development [...]
FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if [...]
Takeda spinout Phathom clinches FDA twin nods for GI infection [...]
Amarin, after 33% revenue decline, aims to ‘stabilize’ US sales [...]
Bayer’s Nubeqa one step closer to blockbuster status thanks to [...]